We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
+49.04%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$18.8B
AUM Growth
+$4.11B
Cap. Flow
-$554M
Cap. Flow %
-2.95%
Top 10 Hldgs %
85.02%
Holding
117
New
8
Increased
21
Reduced
10
Closed
18

Top Buys

Rank Stock Value
1
EXAS
Exact Sciences
EXAS
+$227M
2
DBVT
DBV Technologies
DBVT
+$72.8M
3
KOD icon
Kodiak Sciences
KOD
+$69.2M
4
KRRO icon
Korro Bio
KRRO
+$19.2M
5
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$15.7M

Top Sells

Rank Stock Value
1
GHDX
Genomic Health, Inc.
GHDX
+$627M
2
AMRN
Amarin Corp
AMRN
+$134M
3
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$72.9M
4
NGNE icon
Neurogene
NGNE
+$39.4M
5
CBAY
Cymabay Therapeutics
CBAY
+$29.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.66%
2 Financials 0.01%
3 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CABA icon
51
Cabaletta Bio
CABA
$531M
$8.89M 0.05%
+636,363
New +$7.54M
NXTC icon
52
NextCure
NXTC
$28.8M
$8.45M 0.04%
12,500
– –
ACGN
53
DELISTED
Aceragen Inc
ACGN
$8.39M 0.04%
271,376
– –
RETA
54
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$8.38M 0.04%
+40,983
New +$7.48M
SGMO
55
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$8.37M 0.04%
999,823
– –
PTGX icon
56
Protagonist Therapeutics
PTGX
$9.99B
$8.28M 0.04%
1,174,282
– –
MIRM icon
57
Mirum Pharmaceuticals
MIRM
$5.87B
$8.17M 0.04%
333,333
– –
ABEO icon
58
Abeona Therapeutics
ABEO
$348M
$7.48M 0.04%
91,529
+40,000
+78% +$2.82M
FLGT icon
59
Fulgent Genetics
FLGT
$548M
$7.35M 0.04%
569,444
+444,444
+356% +$5.28M
IFRX icon
60
InflaRx
IFRX
$309M
$7.04M 0.04%
1,778,415
– –
ALBO
61
DELISTED
Albireo Pharma Inc
ALBO
$6.36M 0.03%
250,000
– –
CNST
62
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$6.28M 0.03%
133,333
– –
MTNB icon
63
Matinas BioPharma
MTNB
$2.92M
$5.97M 0.03%
52,647
+12,948
+33% +$750K
ARAV
64
DELISTED
Aravive, Inc. Common Stock
ARAV
$5.92M 0.03%
433,333
-230,755
-35% -$2.04M
TPST icon
65
Tempest Therapeutics
TPST
$16.6M
$5.62M 0.03%
+4,274
New +$6.03M
ORTX
66
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$5.58M 0.03%
40,570
– –
CPRX
67
DELISTED
Catalyst Pharmaceutical
CPRX
$5.03M 0.03%
1,341,902
– –
SYRS
68
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$4.77M 0.03%
69,017
-28,467
-29% -$1.73M
EVFM
69
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$4.67M 0.02%
50,454
+43,651
+642% +$3.68M
NGM
70
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$4.62M 0.02%
250,000
– –
MTEM
71
DELISTED
Molecular Templates, Inc.
MTEM
$4.43M 0.02%
21,115
+4,166
+25% +$599K
CRNX icon
72
Crinetics Pharmaceuticals
CRNX
$8.99B
$4.39M 0.02%
175,000
– –
YMAB
73
DELISTED
Y-mAbs Therapeutics
YMAB
$4.33M 0.02%
138,514
+35,714
+35% +$1.06M
MRKR icon
74
Marker Therapeutics
MRKR
$23.2M
$4.32M 0.02%
150,000
– –
BLUE
75
DELISTED
bluebird bio
BLUE
$3.51M 0.02%
3,088
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q4 2019 Portfolio in Review

As of Q4 2019, Julian Baker held 117 positions worth $18.8B, up 28% from $14.7B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

Julian Baker's Q4 2019 filing shows 8 new, 21 increased, 10 reduced and 18 closed positions. Its largest new stake was Exact Sciences: 2,585,791 shares worth $239M. The largest sale was Genomic Health, Inc., an estimated $627M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Financials and Technology.

  • Julian Baker's largest Q4 2019 buy was Exact Sciences: 2,585,791 shares worth $239M.
  • Julian Baker added most to DBV Technologies in Q4 2019, an estimated $72.8M increase.
  • Julian Baker's biggest Q4 2019 reduction was Amarin Corp, cutting an estimated $134M.
  • Julian Baker fully exited Genomic Health, Inc. in Q4 2019, selling an estimated $627M.
  • Julian Baker's ten largest holdings make up 85% of its $18.8B portfolio in Q4 2019.
  • Julian Baker opened 8 new positions and closed 18 in Q4 2019.
  • Julian Baker's portfolio value rose 28% quarter-over-quarter to $18.8B.

Based on Baker Bros. Advisors's 13F filing for Q4 2019, filed 14 Feb 2020.